BSR Intelligence
Daily intelligence on the peptide research industry.
Independent briefings on regulatory moves, pharma deals, research pipeline shifts and the trust gaps that define this market. Updated daily, sourced inline.
Research Pipeline
Thymosin Alpha-1: The Peptide With the Strongest Clinical Evidence Base — and a Complicated Regulatory Story
Thymosin alpha-1 (Tα1) is approved as a prescription drug in more than 35 countries and has been evaluated in over 80 clinical trials. Yet its US compounding status remains unsettled, and a large 2025 phase 3 trial returned a negative primary endpoint in sepsis. For UK research-procurement professionals, it is arguably the most evidence-rich peptide on the market — and among the most instructive in understanding how clinical nuance shapes regulatory outcome.
24 May 2026
Research Pipeline
GHK-Cu: The Copper Tripeptide Facing Its Second Regulatory Wave — What Research Labs Need to Know
GHK-Cu (copper tripeptide-1) has one of the stronger mechanistic evidence bases among research peptides, spanning wound healing, collagen remodelling, and genomic modulation of over a thousand genes. Following the FDA's April 2026 Federal Register notice, it now sits in the second wave of PCAC review, scheduled before February 2027. This briefing covers its biochemistry, the state of the clinical evidence, and what the split regulatory picture means for UK procurement teams.
24 May 2026
Research Pipeline
TRIUMPH-4 read-out: retatrutide hits 28.7% weight loss but a new dysesthesia signal complicates the path to filing
Eli Lilly's triple-agonist retatrutide produced the highest weight-loss percentage ever recorded in a Phase 3 obesity trial in TRIUMPH-4, but a new dysesthesia signal — not seen in Phase 2 — affected one in five patients on the top dose. With seven further Phase 3 read-outs scheduled across 2026, the next nine months will determine whether retatrutide rewrites the GLP-1 competitive map or carries a safety footnote into the label.
18 May 2026
Research Pipeline
Foundayo (Orforglipron) Sustains Most Injectable GLP-1 Weight Loss in Phase 3b Switch Trial, New Data Show
A Phase 3b trial published in Nature Medicine on 12 May 2026 shows that patients who switched from injectable tirzepatide or semaglutide to once-daily oral orforglipron (Foundayo) retained 75–79% of their prior weight loss over 52 weeks. The data, presented simultaneously at the European Congress on Obesity, add clinical depth to an already-approved drug and sharpen the debate over whether oral small-molecule GLP-1 agonists can serve as maintenance therapy after injectable induction.
15 May 2026
Research Pipeline
Oral Small-Molecule GLP-1 Drugs Reach Deep Brain Reward Circuits, Pointing Towards Addiction Research Applications
A Nature study published 6 May 2026 found that oral small-molecule GLP-1 receptor agonists, including orforglipron and danuglipron, suppress hedonic feeding in mice by modulating a reward circuit in the central amygdala — a mechanism distinct from the hypothalamic appetite pathways activated by peptide-based GLP-1 drugs. The findings add mechanistic weight to a growing body of evidence linking GLP-1 pharmacology to reduced substance use disorder risk.
08 May 2026
Research Pipeline
MOTS-c: The Mitochondrial Peptide Generating Research Interest in Metabolic Disease and Ageing
MOTS-c is a 16-amino-acid peptide encoded not by the nuclear genome but by the mitochondrial genome, placing it in a distinct class from most research peptides. Growing preclinical data point to roles in glucose metabolism, insulin sensitivity, muscle preservation and β-cell protection, though no approved therapeutic use exists and regulatory status in both the US and UK remains firmly research-only.
08 May 2026